Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab in Cutaneous Sarcoidosis
NCT00731757Phase 2Withdrawn
- Sponsor
- Wright State University
- Start
- May 2009
- Primary completion
- Dec 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adalimumab in cutaneous sarcoidosis, sponsored by Wright State University. Primary endpoints: Physician Global Assessment at 24 weeks and Physician Target Lesion Assessment at 24 weeks. Planned start May 2009; status: withdrawn.
02
Drugs
03
Conditions
cutaneous sarcoidosis
Beyond the preview
Go deeper on NCT00731757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00731757.